WindMIL Therapeutics, is a clinical stage company developing bone marrow derived, Marrow-Infiltrating Lymphocytes (MILs_) for cancer immunotherapy to treat solid and liquid cancers.
WindMIL Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://windmiltherapeutics.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address1812 Ashland Avenue, 1st Floor, Suite 100, MD, 21205BaltimoreUnited States
1812 Ashland Avenue, 1st Floor, Suite 100, MD, 21205
Baltimore
United States
Contact Number+1 410-558-1906
+1 410-558-1906
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In June 2018, WindMIL Therapeutics raised $32.5 Mn in Series B financing led by Qiming Venture Partners USA. Other new investors included Medivate Partners and Camden Partners Nexus. Existing investors Domain Associates and FOXKISER also participated in Series B financing. Earlier in April 2016, WindMIL raised $10 Mn in a series A round led by Domain Associates.